Global Virus Testing Kits Market Size, Share, Trends and Forecast 2026-2033

Global Virus Testing Kits Market Size, Share, Trends and Forecast 2026-2033

Market Forecast Snapshot, 2025-2033

The market, stated plainly

The global virus testing kits market was valued at USD 16.23 billion in 2025 and is forecast to reach USD 31.77 billion by 2033. Eight periods of compounding gives a 1.9575x expansion and an implied compound annual growth rate of 8.7583%, stated throughout as 8.76%. Incremental revenue across the window is USD 15.54 billion.

The thesis: the season is the market

This category stopped being a pandemic market in 2023 and has not finished telling anybody. What replaced the pandemic is not one business but two, wearing a single label.

Respiratory testing is episodic. It runs on how long and how severe a season turns out to be, it carries a fixed instrument and manufacturing cost base that does not flex, and its revenue in any given year is a function of epidemiology rather than strategy. Programme testing — blood-borne viruses, sexually transmitted infections, human papillomavirus, viral load monitoring — is contracted, policy-driven and non-discretionary. One of these businesses can have a bad year because the winter was mild. The other cannot.

2025 demonstrated the difference inside single companies. Abbott's diagnostics sales fell 4.3% to USD 8,937 million, but Core Laboratory grew 2.4% to USD 5,360 million and Point of Care grew 3.1% to USD 606 million, while Rapid Diagnostics fell 18.1% to USD 2,454 million. The reconciling item is disclosed: COVID-19 testing-related sales fell from USD 747 million to USD 297 million, a decline of 60.24%. QuidelOrtho's respiratory revenue fell 20.2% to USD 402.1 million while its flu revenue grew 3% — and the company still improved its adjusted EBITDA margin by 240 basis points to 22% by taking operating expenses down 5%. Roche's Molecular Lab grew 4% at constant exchange rates while Near Patient Care fell 3%. bioMerieux grew 6.2% organically with BIOFIRE respiratory panels up just 1% and BIOFIRE non-respiratory panels up 10%.

That spread is not a share table. It is a COVID comparison, and reading it as a share table is the most common error made about this market.

Three findings that carry the forecast

One. The installed base is the asset, not the assay. A kit is a consumable sold into a placement. bioMerieux added 1,800 BIOFIRE units net in 2025 against 1,350 in 2024, and grew its SPOTFIRE installed base 110% to 6,400 instruments while SPOTFIRE sales grew 84% to EUR 168 million. Those placements convert into cartridge revenue across the whole forecast window regardless of what any individual season does. The competitive question is not whose assay is better; it is who owns the box.

Two. Multiplexing is deflationary per test and inflationary per episode. A syndromic panel of fifteen to twenty-five targets replaces six to eight single-target assays, so price per target falls and the single-target lines lose volume. But the panel is priced above any single assay, it is ordered where no single assay would have been ordered, and it captures co-infections and differentials that previously went untested. Which effect dominates is empirical, and 2025 says the second is winning at the platform layer: non-respiratory BIOFIRE panels grew 10% and SPOTFIRE grew 84%, both panel businesses gaining volume.

Three. The forecast rate is above the run-rate and above the participants' own plans, and that is stated rather than smoothed. The 2025 growth rates for the molecular core were 4% at Roche, negative 0.7% at Abbott and 1% for bioMerieux respiratory panels. bioMerieux's own GO·28 strategic plan targets sales growth of 7% compound from 2024 to 2028. This report forecasts 8.76% for the whole market over a longer window, which requires the market to outgrow its most explicitly guided large participant. The sensitivity is in the risk chapter and it is not comfortable: if the base contracts 3% in 2026 as the COVID tail completes, the remaining seven years must compound at 10.5537% to arrive at USD 31.77 billion.

What is inside the perimeter

This report measures kits and panels for viral detection across all settings and all three formats — molecular, antigen and serology. That is a materially broader perimeter than the syndromic respiratory panel market, one published estimate of which puts molecular respiratory panels at USD 1.2 billion in 2025 rising to USD 2.2 billion by 2035 at 6.0%. The syndromic core is a small, high-value layer inside the kit market, not a synonym for it.

One boundary note governs how the competitive landscape should be read. No participant in this market discloses a virus-testing-kits revenue line. Segment disclosures and installed-base movements are evidence; share percentages are not available and are not asserted anywhere in this report.

Further reading from this desk

• The Reagent Is the Business — why an instrument placement is a customer acquisition cost, and why the cartridge is the product.
• Fifteen Per Cent a Year — how a procedure-code schedule, rather than a product, sets the ceiling on diagnostics revenue growth.
• The Twenty-Eight Day Rule Is Over — the same argument in a different market: demand that is mandated is worth more than demand that is discretionary.

Related reports

• Global Home-Based Molecular Testing Market — the consumer channel these kits feed.
• Global Diagnostic Tests Market — the USD 118.60 billion aggregate this market sits inside.
• Global Next-Generation Sequencing Market — the surveillance layer that sequences what these kits detect.
• Global Clinical Laboratory Services Market — the capacity that runs the panels.
• Global Point-of-Care Testing Market — the setting where decentralised viral testing competes.

Method note

Data are drawn from fiscal 2025 results announcements and filings of the named participants, from United States regulatory documents including final rules and agency guidance, and from World Health Organization regional surveillance reporting for outbreak volumes. Installed-base figures are as disclosed by the manufacturer concerned and are not comparable across companies. Volume is left unquantified: no participant discloses a global unit count for viral testing kits, and a constructed figure would imply a precision the evidence base does not carry.

Table of Contents

Table of Contents

1. Executive Summary
1.1 Market Forecast Snapshot 2026-2033
1.2 The Two Businesses Under One Label
1.3 Why 8.76% Is Above the Current Run-Rate

2. Market Definition and Research Methodology
2.1 What Counts as a Virus Testing Kit
2.2 Perimeter Against Adjacent Categories
2.3 Installed Base as the Unit of Analysis
2.4 Base Year Construction

3. Market Size and Forecast 2026-2033
3.1 The 2025 Base and Its COVID Content
3.2 The 2033 Terminal Value
3.3 The Sensitivity That Matters
3.4 Regional Distribution

4. Market Dynamics
4.1 Drivers: Multiplex Conversion, Programme Testing, Outbreak Response
4.2 Restraints: Season Variability, China Pricing Reform, Antigen Substitution
4.3 Opportunities: Decentralised Platforms, Surveillance Sequencing, Syndromic Menus
4.4 Challenges: Fixed Cost Base, Emergency Dependence, Tender Pressure

5. Segmentation
5.1 By Format: Molecular, Antigen, Serology
5.2 By Pathogen: Respiratory, Blood-Borne, STI, Enteric, Emerging
5.3 By Setting: Central Laboratory, Point of Care, Home
5.4 By Geography

6. Competitive Landscape
6.1 The Eight Participants of Scale
6.2 Reading the 2025 Spread Correctly
6.3 Installed Base and Menu Breadth
6.4 What Cannot Be Known From Filings

7. Value Chain
7.1 Reagent and Component Supply
7.2 Panel Manufacture
7.3 Instrument Placement
7.4 Tender and Distribution
7.5 The Payer Step, by Country

8. Technology Landscape
8.1 Syndromic Multiplex Panels
8.2 Rapid Antigen Lateral Flow
8.3 Isothermal and Sample-to-Answer Platforms
8.4 Sequencing-Based Surveillance
8.5 The Economics of Multiplexing

9. Regulatory and Policy Environment
9.1 Emergency Use Authorisation for Novel Pathogens
9.2 CLIA and the Setting of Use
9.3 Laboratory Developed Tests After the Vacatur
9.4 In Vitro Diagnostic Regulation in Europe
9.5 WHO Prequalification and Programme Procurement

10. Investment and Capital Formation
10.1 Placements as Capital Expenditure
10.2 The Cost of COVID-Era Assumptions
10.3 Where Investment Is Redirecting

11. Market Risk Assessment
11.1 Eight Risks and Their Transmission Channels
11.2 The Correlated Pair
11.3 What Would Break 8.76%

12. Future Outlook and Strategic Recommendations

13. Appendix and Methodology Notes

Competitive Landscape

Competitive Landscape

This market contains eight participants of genuine scale, and its competitive dynamics are best read by looking at what happened inside each of them in 2025 rather than at any share estimate. No company in this market discloses a virus-testing-kits revenue line. That single fact should govern how the competitive landscape is described: segment disclosures and installed-base movements are evidence, and share percentages are inference.

The 2025 spread, and why it is not a share signal

Four large participants reported in the same twelve months, and their headline diagnostics growth rates ranged from a decline of 4.3% to growth of 6.2%. Read carelessly, that looks like share loss and share gain. Read properly, it is a COVID comparison.

Abbott reported worldwide sales of USD 44,328 million for 2025 and diagnostics sales of USD 8,937 million, down 4.3% reported and 4.5% organic. Inside the division the picture divides cleanly: Core Laboratory USD 5,360 million, up 2.4%; Molecular USD 517 million, down 0.7%; Point of Care USD 606 million, up 3.1%; Rapid Diagnostics USD 2,454 million, down 18.1%. The division’s United States Rapid Diagnostics line fell 20.8% to USD 1,538 million. The reconciling item is disclosed on the same page: COVID-19 testing-related sales fell from USD 747 million to USD 297 million, a decline of 60.24%. Nothing about Abbott’s competitive position changed by eighteen points; a product line worth roughly half a billion dollars of annual revenue left the comparison.

QuidelOrtho illustrates the same mechanism from the other direction. Total revenue was USD 2,730.2 million, down 1.9%, and respiratory revenue was USD 402.1 million, down 20.2% – but flu revenue grew 3% and total revenue excluding COVID-19 rose 1.8%. Respiratory was 14.73% of company revenue, so a fifth of a seventh of the business explained the whole of the decline. Laboratories revenue grew 6%.

The finding inside QuidelOrtho’s numbers is more interesting than the decline. Adjusted EBITDA was USD 597 million at a 22% margin, up 240 basis points, while GAAP results included a USD 701 million non-cash goodwill impairment and a net loss of USD 1.13 billion. The operating business improved its margin by 240 basis points in the same year its respiratory revenue fell a fifth, and it did so because operating expenses fell 5% on cost-savings initiatives. That is what a fixed cost base being cut to fit a smaller seasonal business looks like. The impairment is the accounting admission that the 2022 combination was priced on respiratory volumes that did not persist, and the 240 basis points are the operating answer to the same problem.

Roche’s diagnostics division recorded CHF 13,847 million, up 2% at constant exchange rates and down 3% in Swiss francs. Inside it, Core Lab was CHF 7,614 million at 0% and Molecular Lab was CHF 2,527 million, up 4%, while Near Patient Care fell 3% to CHF 1,983 million and Pathology Lab grew 14% to CHF 1,723 million. Asia-Pacific fell 12% on Chinese healthcare pricing reforms, which is the single most important geographic fact in this market and is treated separately in the risk chapter.

bioMerieux grew sales 6.2% organically to EUR 4,070 million, with contributive operating income of EUR 728 million, a 17.9% margin, up close to 160 basis points at constant exchange rates and scope. Its net income fell 8% to EUR 398 million on a partial impairment of the VITEK REVEAL technology, which is a separate matter from virus testing. The composition of its growth is what matters here: BIOFIRE non-respiratory panels reached EUR 598 million, up 10% organically, with a net installed base expansion of 1,800 units against 1,350 in 2024; BIOFIRE respiratory panels grew just 1% organically; and SPOTFIRE generated EUR 168 million, up 84% in value and more than 100% in volume, with an installed base of 6,400 instruments, up 110%. Microbiology grew 4% organically but was held back by a double-digit decline in China; excluding China it grew 6.3%.

Consolidated at the platform, fragmented at the kit

The structure of this market is two layers with different concentration. The platform layer – the instruments, the syndromic menus and the global distribution – is concentrated in the eight participants named above, and entry is effectively closed: a competitor needs a validated menu, a service network and a regulatory footprint across dozens of jurisdictions. The kit layer – single-target assays, rapid antigen tests and regional products – is fragmented, price-competitive and exposed to tender, with many producers operating inside a single country or a single programme.

That two-layer structure explains the pattern of consolidation. Larger participants have been buying or building menu breadth and decentralised platforms rather than capacity, because capacity is easy and a menu is not. It also explains why this report records recent merger and acquisition activity as present while describing the consumer-facing home segment elsewhere in this cluster as having none: consolidation is happening in platforms and menus, not in brands.

Where competition actually operates

Three levers, and none of them is assay performance, because performance is now broadly adequate across the tier-one set.

Installed base. bioMerieux’s 1,800 BIOFIRE placements and 110% SPOTFIRE installed-base growth are the clearest available measure of competitive success in this market, because a placement converts to multi-year cartridge revenue. Every participant is running the same play: put a box in a laboratory or a clinic and let the consumable annuity follow. The instrument is a customer acquisition cost dressed as capital equipment.

Menu breadth and syndromic coverage. A panel with twenty targets is a different product from a panel with eight, and the difference is measured in what a clinician can rule out rather than rule in. Menu breadth is also the most defensible asset in the kit layer, because each additional target is a validation cost that a smaller competitor cannot amortise.

Tender access and programme qualification. Outside the reimbursed markets, kits are bought by ministries and programmes through tender and, for donor-funded procurement, through prequalification. Access to those channels is a competitive asset that has nothing to do with the product and everything to do with registration, local presence and price.

What cannot be known from filings

Three things should be listed as unknown rather than estimated.

First, no participant discloses virus testing kits as a revenue line. Abbott’s Molecular segment and Roche’s Molecular Lab customer area are close proxies but not the same perimeter, and neither includes antigen or serology. Second, installed-base numbers are disclosed selectively, by company and by year, so a cross-company placement league table cannot be constructed. Third, private and regional producers, particularly in China and India, are material in unit terms and effectively invisible in revenue terms.

Any published statement that this market lacks tier-one participants should be treated as an error. Eight companies with disclosed segment revenues in the hundreds of millions to billions of dollars operate in it, and the two largest diagnostics companies in the world are among them. This report describes the structure as moderately consolidated at the platform layer with high competitive intensity at the kit layer, and it counts eight participants of tier-one scale.

Value Chain

Value Chain

The virus testing kit value chain has five stages, and the distribution of margin across them has changed decisively since 2022. Two stages now earn an adequate return: instrument placement and menu ownership. Three earn a competitive one: component supply, kit manufacture and distribution.

Stage one: reagent and component supply

Every format depends on a small number of upstream inputs: enzymes for amplification, primers and probes, antibodies for antigen and serology formats, nitrocellulose for lateral flow membranes, and the plastics and foils that make a cartridge. These are supplied by a concentrated group of specialists, and the concentration is a structural feature rather than an accident of history.

Two consequences follow for the chain. First, a kit maker’s gross margin is partly set by an upstream supplier it does not control, and the exposure is highest in exactly the formats that grew fastest during the pandemic, because capacity was added under emergency conditions and has since been rationalised. Second, the ability to secure supply at scale was a genuine competitive advantage between 2020 and 2022 and has reverted to a normal procurement function, which means it no longer supports a premium.

Stage two: kit and panel manufacture

Manufacturing economics depend on volume per SKU, and the SKU problem is severe in this market. A panel sold into twenty countries with four sample types and three instrument generations is not one product; it is dozens of validations of the same chemistry. A single-target antigen test has the opposite profile: a simple product made in very large volumes at a low unit price, where margin comes entirely from scale and cost control.

This is why the platform participants concentrate on panels and the fragmented tail concentrates on single-target kits. The panel business needs regulatory and validation capacity; the single-target business needs cost discipline and a tender relationship. They are different companies with different cost structures, and they compete for the same test occasion.

Stage three: instrument placement

Placement is where the money is committed and where the annuity is created. An instrument, its service contract and its menu validation are a fixed investment by the manufacturer or the laboratory, recovered across consumables over years. The accounting treatment varies, but the economics do not: the placement is not the sale, it is the acquisition of a customer.

2025’s disclosed placement numbers are the best available lead indicator in this market. bioMerieux added 1,800 BIOFIRE units net, against 1,350 in 2024, and grew its SPOTFIRE installed base 110% to 6,400. Those placements will convert into cartridge revenue across the forecast window regardless of how any single respiratory season turns out, which is why a mild season damages a year and not a cycle.

The converse is the risk that sits in the same mechanism. An installed base is a multi-year obligation to support and a multi-year assumption about cartridge pull. If the season is mild twice in succession, the installed base does not shrink but its utilisation does, and the manufacturer has already spent the capital.

Stage four: distribution, tender and the institutional buyer

Outside the reimbursed markets, kits are bought institutionally: by ministries of health, by national public health institutes, by hospital groups and, for donor-funded programmes, through procurement agents operating against prequalification lists. Price is set by tender, by volume commitment and by the terms of a framework agreement, and it is not set by the manufacturer.

This stage is where the most violent price pressure in the market originates, and 2025 gave a clear example. Roche’s Asia-Pacific diagnostics sales fell 12% because of healthcare pricing reforms in China, and bioMerieux’s microbiology franchise was held back by a double-digit decline in China against 6.3% growth excluding it. Volume-based procurement converts a market from price-per-test to price-per-contract, and a kit maker that does not win the contract loses the whole province rather than a share of it.

Stage five: the payer step, which differs by country

The final stage of the chain is not the patient; it is whoever pays, and the identity of that party determines the margin on the identical product.

In the United States, a respiratory panel is billed to a payer under a procedure code and reimbursed at an administered rate, so the kit maker sells into a laboratory whose revenue is a schedule entry and whose cost discipline passes back up the chain as price pressure on the kit. In Europe, much testing sits inside a hospital budget or a diagnosis-related group, so the test competes for money with everything else the hospital does, and the incentive is to minimise tests per admission. In low-resource and programme settings, the buyer is a ministry or a donor, price is negotiated at the programme level, and the constraint is the total budget envelope rather than the cost per test.

Three buyers with three different elasticities explain a pattern that otherwise looks irrational: the same twenty-target panel can be a high-margin product in one market and a loss-making tender in another, and manufacturers choose which markets to serve accordingly. It also explains why decentralised platforms are growing fastest where the payer is a programme rather than a hospital – the programme is buying access, not cost saving.

Where value sits in the chain

Two stages capture it. Menu ownership earns because a validated syndromic panel is the only part of the chain that cannot be replicated without regulatory and clinical investment, and because the panel determines what the clinician can ask. Instrument placement earns because it converts a product sale into an annuity and because the placement decision is made once and defaults for years.

Everything between those two stages is competitive. Component supply is contested by specialists, kit manufacture by anyone with a filling line and a validation budget, and distribution by whoever offers the best terms. The strategic implication for anyone entering this market is uncomfortable but clear: the entry point that looks cheapest, making a kit, is the one that earns the least, because it sits between the two stages where the margin is actually held.

Investment Activity

Investment and Capital Formation

Capital in this market is not being deployed to add capacity. It is being deployed to move the testing closer to the patient and to widen the menu, and the two largest disclosed commitments of 2025 are both placements rather than plant.

Placements are the capital expenditure

A decentralised platform is a fixed asset installed at a customer site, recovered across consumables over several years. The number that matters in the year it is spent is the placement count; the number that matters afterwards is cartridge pull. bioMerieux disclosed both directions of that trade in 2025: a net expansion of 1,800 BIOFIRE units against 1,350 in the prior year, and a SPOTFIRE installed base of 6,400 instruments, up 110%, with SPOTFIRE sales up 84% in value and more than 100% in volume.

Read as a capital programme, that is a company spending on customer acquisition and being paid back through reagent. Read as a return, it explains why the growth rate in the decentralised tier is an order of magnitude above the growth rate in the laboratory tier: the base is small and the placement is still compounding. A 110% increase in installed base is not a market-share event; it is an investment decision.

Laboratory-bound capacity is a different proposition. It is shared across all of a laboratory’s testing, not just viral testing, so a kit maker does not finance it and cannot direct it. The implication for this market is that the capital intensity sits mostly with the customer, which is why the participant-level capital intensity in this report is high at the instrument and manufacturing layer while the incremental capacity is close to free at the kit layer.

The cost of COVID-era assumptions, now quantified

QuidelOrtho’s 2025 results contain the clearest statement of mispriced capital in this market. The company recorded a USD 701 million non-cash goodwill impairment related to prior acquisition accounting, contributing to a GAAP operating loss of USD 0.92 billion and a net loss of USD 1.13 billion, against a full-year revenue line of USD 2,730.2 million. The impairment is the accounting recognition that the carrying value of an acquisition was set when respiratory testing volumes were higher than they turned out to be.

The operating response in the same year is the more instructive half. Adjusted EBITDA was USD 597 million at a 22% margin, up 240 basis points, with operating expenses down 5% on cost-savings initiatives and free cash flow of negative USD 77 million after a one-time ERP conversion investment. A company that lost a fifth of its respiratory revenue improved its operating margin by taking cost out faster than revenue fell. That is what the fixed cost base in a seasonal business permits, and what it costs to do.

Where investment is redirecting

Three directions, all visible in disclosed guidance rather than in inference.

From laboratory to point of care. SPOTFIRE’s 110% installed-base growth and 84% sales growth are the clearest directional signal in the market, and they are happening in a portfolio whose respiratory panels grew 1%. The money is following the setting, not the pathogen.

From respiratory to non-respiratory panels. BIOFIRE non-respiratory panels reached EUR 598 million on 10% organic growth while respiratory grew 1%. The investment logic is straightforward: a non-respiratory panel is not exposed to how severe a winter is.

From volume to menu. Syndromic breadth is being extended rather than capacity being added, because capacity in this market is not the constraint.

The guidance that constrains the forecast

bioMerieux’s own GO·28 strategic plan targets sales growth of 7% compound at constant exchange rates and scope from 2024 to 2028, with contributive operating income growing at least 10% a year and a margin improvement of around 500 basis points across the period. Its 2026 guidance is sales growth of 5% to 7% at constant exchange rates and scope, against an expected negative currency effect of EUR 50 million to EUR 60 million.

Those are the most explicit forward commitments made by any participant in this market, and both sit below the 8.76% this report forecasts for the market as a whole. That is not a contradiction, but it is a constraint that should be stated: the forecast requires the market to grow faster than the most transparent large participant’s own plan, on the argument that the market includes faster-growing decentralised and programme segments that a single company’s mix does not capture. If that argument fails, the number fails with it.

Consolidation, and what is being bought

Merger and acquisition activity is present but narrow. What is being acquired is menu and channel: platform companies buying assay portfolios, and larger groups buying regional distribution and installed base. What is not being acquired is pure respiratory exposure. The 2022 combination that produced the USD 701 million impairment is the reference transaction for why, and no comparable premium has been paid for a respiratory-weighted asset since.

For an investor, the underwriting reduces to three variables. Whether the season normalises onto a larger multiplex base. Whether programme testing keeps expanding on policy commitments rather than commercial ones. And whether China’s pricing reform reaches a floor rather than continuing to reset. None of those is a product question, which is the point: in a market where the platforms have converged and the menus are broadly adequate, the returns are set by epidemiology, policy and procurement.

Technology & Innovation

Technology Landscape

Four detection formats compete in this market, and they are not substitutes for one another so much as tiers of a cost-and-consequence ladder. The technology question that matters commercially is not which format is most sensitive. It is where multiplexing stops paying for itself.

Syndromic multiplex panels

The panel is the premium product in this market. A respiratory syndromic panel simultaneously detects and differentiates influenza A and B, respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, parainfluenza, adenovirus, rhinovirus and, in the larger formats, bacterial targets that change antibiotic decisions. The target count in commercial panels runs from roughly fifteen to twenty-five. The largest published segmentation of this specific sub-category puts molecular respiratory panels at USD 1.2 billion in 2025, rising to USD 2.2 billion by 2035 at 6.0%, with multiplex formats accounting for just under half of it – which situates the syndromic core as a small, high-value layer inside the far larger kit market measured in this report.

The technology has converged. Sample-to-answer cartridge platforms with automated extraction, amplification and detection are the standard, and the differentiation now sits in three places: the number of targets, the hands-on time, and the time to result. The engineering work has moved from chemistry to fluidics and contamination control, because the constraint on throughput in a busy laboratory is no longer the amplification step but the labour around it.

Rapid antigen lateral flow

Antigen tests trade analytical sensitivity for cost, speed and the absence of equipment. They are the correct technology for a triage decision in a pharmacy or a home, and the wrong technology for a decision that depends on ruling out a low viral load. Their commercial role in this market is to hold the convenience end, and their strategic importance to the kit makers is defensive: an antigen test sold at a few dollars protects a relationship that a molecular test at many times the price cannot reach.

Substitution runs in one direction more than the other. Antigen converts molecular volume at the convenience end when cost pressure dominates; molecular converts antigen volume back when a clinical decision requires sensitivity or when a panel is reimbursed at a level that makes the differential irrelevant. The net effect over the forecast window is a slow mix shift towards molecular in reimbursed settings and a durable antigen base in self-pay and low-resource settings.

Isothermal and sample-to-answer platforms

The decentralised tier is where the growth rate is highest and the evidence is unambiguous. bioMerieux’s SPOTFIRE platform generated EUR 168 million in 2025, up 84% in value and more than 100% in volume, with an installed base of 6,400 instruments, up 110%. That is a sample-to-answer molecular platform scaling at more than double the rate of any laboratory-bound product in the same portfolio, and it is happening while the company’s respiratory panels grew 1%.

Cartridge-based decentralised platforms matter most where the alternative is no test at all. The World Health Organization’s African regional office reports that more than 50,000 GeneXpert cartridges were deployed for the mpox response across 2024 and 2025, decentralising testing far beyond central reference laboratories, and that 51 laboratories across more than 30 countries participated in a mpox external quality assessment with an 89.4% detection success rate. That is a working demonstration of the decentralised model at scale, and it is the template for outbreak response generally.

Sequencing-based surveillance

A fourth format does not compete with the other three at all, and it is the most durable addition to this market in a decade. Genomic surveillance sequences the pathogen rather than detecting it, which makes it a different product with a different buyer: public health rather than the clinic. WHO’s African regional office reports genomic sequencing capacity in 46 of 47 member states and more than 2,700 mpox sequences by December 2025.

The commercial consequence is a demand line that is not seasonal, not dependent on a patient presenting, and funded from a surveillance budget rather than a testing budget. It consumes library preparation reagents and sequencing consumables rather than panels, which places it at the boundary between this market and the sequencing market, and it grows with the number of pathogens under surveillance rather than with the number of patients tested.

The economics of multiplexing, stated precisely

Multiplexing does two things to revenue at once, and the net effect is what determines whether this market grows at 8.76% or at 4%.

On one side, a panel is deflationary per target. If a clinician previously ordered six single-target assays and now orders one twenty-target panel, the revenue attributable to each target falls sharply, and the single-target product lines lose volume outright. A laboratory that converts to panels reduces its cost per result while the kit maker’s revenue per target declines.

On the other side, a panel is inflationary per episode. The panel is priced above any single assay, it is ordered in situations where a single assay would not have been ordered at all, and it captures co-infections and differential diagnoses that would previously have gone untested. The volume of testing expands because the test answers more questions.

Which effect dominates is an empirical question, and the 2025 disclosures suggest the second is currently winning at the platform layer: bioMerieux grew non-respiratory BIOFIRE panels 10% while growing its installed base 1,800 units, and grew SPOTFIRE 84% on a decentralised sample-to-answer format. Both are panel businesses gaining volume. The same disclosures show the first effect working in the respiratory line, where panels grew only 1% – a mature, heavily penetrated, season-dependent segment where conversion is largely complete and the only remaining variable is how many people get ill.

What the technology frontier actually is

Not target count. The binding constraints are ambient stability and cost per test at the point of use. A decentralised platform is only decentralised if its reagents do not need a cold chain, and a panel is only adopted in a low-resource setting if its price per test fits the programme budget rather than the laboratory budget. The engineering work that matters commercially is therefore lyophilisation, extraction-free chemistry and cartridge design that holds a result stable across a temperature range.

That is a less glamorous frontier than sequencing, and it is where the growth in this market will come from: the same syndromic logic, delivered at a price and a temperature that the next billion tests can bear.

Market Risk

Market Risk Assessment

The forecast of 8.76% survives a normal range of outcomes but fails a specific combination, and the combination is plausible enough to be modelled explicitly. The eight risks below are ordered by how directly each attacks the revenue line, with the transmission channel stated for each.

1. Season severity and negative operating leverage

Respiratory demand is a function of how long and how severe a season is, and the cost base that serves it does not flex within a year. Transmission channel: a mild season reduces revenue without reducing the instrument placements, the manufacturing footprint or the service organisation that support it, so margin falls faster than revenue. QuidelOrtho’s 2025 experience shows both sides: respiratory revenue down 20.2% and adjusted EBITDA margin up 240 basis points, achieved only by cutting operating expenses 5%. A company that has already taken that cost out has less room the second time.

2. Residual COVID comparison

COVID revenue has not finished leaving the base. Abbott’s COVID-19 testing-related sales were USD 297 million in 2025 against USD 747 million in 2024, and QuidelOrtho’s COVID line was still large enough to drive a 20.2% fall in respiratory revenue while flu grew 3%. Transmission channel: as long as any COVID revenue remains in the comparison, reported growth understates the underlying business in the year it falls and overstates the difficulty of the following year. The reverse is the real risk to the forecast: once the tail is gone, the growth rate has to be earned rather than recovered, and the disclosed 2025 core rates were 4%, negative 0.7% and 1%.

3. China pricing reform and volume-based procurement

This is the most material single geographic risk in the market. Roche’s Asia-Pacific diagnostics sales fell 12% because of healthcare pricing reforms in China. bioMerieux’s microbiology franchise grew 4% organically only because growth of 6.3% outside China was offset by a double-digit decline in China, and its fourth quarter was affected by a mid-single-digit organic decrease there. Abbott reported challenging conditions in China including the impact of volume-based procurement programmes in core laboratory.

Transmission channel: volume-based procurement converts a price-per-test market into a price-per-contract market, so a lost tender removes a province rather than a share, and the winning price is set by the buyer. The effect is a step change in revenue rather than a gradual erosion, which is why it belongs at the top of the risk register and why the forecast requires a floor rather than a recovery.

4. Antigen substitution at the convenience end

Antigen tests are cheaper, need no equipment and deliver a result in minutes. Transmission channel: in self-pay and low-resource settings, antigen converts molecular volume whenever cost pressure dominates the decision, and the conversion is sticky because it changes the site of testing rather than merely the product. Substitution risk in this report is assessed as high for that reason.

5. Laboratory competition under the laboratory developed test framework

The FDA’s 2024 rule that would have brought laboratory developed tests into the device framework was vacated on 31 March 2025, and the agency reverted to the pre-2024 text on 19 September 2025. Transmission channel: large laboratories can build and validate their own syndromic panels instead of buying a manufacturer’s, and they do so wherever volume justifies it. That caps the price a kit maker can charge for a panel that a reference laboratory could reproduce, and it places a competitor inside the largest customers. The vacatur is deflationary for kit pricing, and it is the reason menu breadth has to be defended continuously rather than once.

6. Dependence on emergency declarations for novel-pathogen demand

A meaningful part of non-seasonal demand exists only while a public health emergency is declared: the mpox response volumes, the COVID volumes before them, and the accelerated authorisation pathways that let a new assay reach the market in weeks. Transmission channel: when a declaration ends, both the demand and the authorisation basis for the products serving it end together. That demand is real, it is large, and it is not addressable by commercial planning.

7. Installed-base utilisation

Every placement is a multi-year support obligation against an assumption about cartridge pull. bioMerieux’s 1,800 BIOFIRE additions and SPOTFIRE’s 6,400 instruments are now in the base. Transmission channel: if utilisation per instrument falls, the manufacturer carries the service cost without the consumable revenue, and the placement converts from an asset to a liability. This is the mechanism by which two consecutive mild seasons do permanent damage even though neither season does.

8. Procedure-code and coverage change in the United States

Respiratory panels are reimbursed through procedure codes in the United States, and the kit maker’s price passes through a laboratory whose revenue is a schedule entry. Transmission channel: a downward revision to a panel code compresses the laboratory’s margin, which passes back up the chain as pressure on kit price, and a narrowing of coverage criteria reduces the number of occasions on which a panel is ordered at all.

The correlated pair

Risks 1 and 3 should be modelled together, not separately. A mild respiratory season and a Chinese procurement reset in the same fiscal year hit volume and mix simultaneously, and they are not independent: both reduce the share of revenue coming from high-value syndromic panels, so the blended price per test falls at the same time as the test count. That is how a market growing at 8.76% delivers a year of low single digits without any single catastrophic event.

The second correlated pair is 2 and 7. The completion of the COVID tail removes the last easy comparison at exactly the point when the 2025 placements begin requiring utilisation to justify themselves. If cartridge pull is weak in the first full year of a large installed base, the market records a growth rate that looks like a demand problem and is actually a timing problem.

What would break 8.76%

The rate is one number with three requirements behind it, and each can be tested against published disclosures.

Requirement one: the season normalises onto a larger multiplex base. The syndromic core is small and growing at 6.0% on one published estimate of the molecular respiratory panel market. For the whole kit market to compound at 8.76%, non-respiratory panels and programme testing have to carry more of the growth than respiratory does. bioMerieux’s 10% non-respiratory growth against 1% respiratory growth is exactly the pattern the forecast needs, and it is one company’s evidence.

Requirement two: China reaches a floor. A 12% decline in Roche’s Asia-Pacific diagnostics revenue and a double-digit decline in bioMerieux’s Chinese microbiology business are not consistent with an 8.76% market rate continuing for eight years. The forecast assumes the reset is a step change followed by stability rather than a continuing annual reduction. If procurement rounds keep resetting prices, the market’s arithmetic changes permanently.

Requirement three: the decentralised tier keeps compounding. SPOTFIRE’s 84% value growth on a 110% installed-base increase carries a large share of the forecast’s optimism. It is a small base inside a large market, and small bases can compound at those rates for several years before a law of large numbers applies. The forecast assumes they do so for longer than the current year.

For scale, the sensitivity that matters most: if the 2026 base contracts 3% to USD 15.74 billion as the COVID tail completes, the remaining seven years must compound at 10.5537% to reach USD 31.77 billion. That is the real requirement embedded in the headline, and it is above the 7% compound growth that the most transparent large participant has committed to in its own strategic plan. An investor should treat 8.76% as the optimistic end of a defensible range rather than as a central expectation, and should treat the disclosed non-respiratory panel growth rate as the leading indicator of whether it will be achieved.

Regulatory Landscape

Regulatory and Policy Environment

Two regulatory variables determine the size of this market, and neither of them is about product safety. The first is which authorisation route a product travels, because that sets how long the product can be sold. The second is whether a laboratory may build its own test, because that sets how much a kit maker can charge for one.

Emergency authorisation and its expiry

The United States framework has two routes of very different duration. A clearance under 510(k) or a de novo classification produces a marketing authorisation that persists, with a defined intended use, a label and a stable commercial life. An Emergency Use Authorization under Section 564 produces a permission that exists only for the duration of the declaration justifying it, and that can be terminated or revoked before the commercial cycle is complete. The authorisation for a novel-pathogen assay typically permits a narrower intended use than a cleared product would carry, and prohibits marketing outside it.

This distinction shapes the revenue base of the market more than any other single rule. A large share of the assays developed for mpox, for COVID-19 and for each new influenza subtype reached the market through the emergency route, and their revenue exists under the same condition as their authorisation. The consequence for forecasting is that a portion of non-seasonal demand is a policy variable rather than a commercial one, and should be modelled with an explicit expiry assumption rather than as a permanent line. The consequence for marketing is that a product authorised for three targets cannot be sold as a twenty-target panel, however capable the underlying chemistry.

CLIA and the setting of use

The Clinical Laboratory Improvement Amendments determine where a test may be performed and by whom, and for a kit maker the CLIA categorisation of a product is as commercially decisive as its clinical performance. A test categorised as moderately or highly complex can only be run in a laboratory holding the corresponding certificate, which confines the kit to the central laboratory channel. A waived test may be performed by personnel without formal laboratory training in a waived setting, which opens point of care, physician offices, pharmacies and, where the labelling permits, the home.

The commercial consequence is direct: the addressable market for a waived assay is several times the addressable market for an identical non-waived assay, and the difference has nothing to do with how well the test detects a virus. Waiver is obtained by demonstrating that the test is simple and that its errors are inconsequential when performed by an untrained operator, which is an argument about device design and result interpretation rather than about analytical sensitivity. This is why so much development effort in this market goes into making a complex test work in a simple way.

Laboratory developed tests and the 2025 vacatur

The most consequential regulatory sequence in this market over the last two years was not about kits at all. On 6 May 2024 the FDA issued a final rule amending the definition of in vitro diagnostic products in 21 CFR 809.3(a) to add the words including when the manufacturer of these products is a laboratory, which would have subjected laboratory developed tests to the device framework. On 31 March 2025 a United States district court vacated that rule. On 19 September 2025 the FDA issued a final rule reverting to the text of the regulation as it stood before the 2024 amendment took effect.

For kit makers, the outcome is double-edged and should be read carefully. Had the rule survived, every laboratory developed syndromic panel would have required device authorisation, and the panel layer would have belonged to manufacturers with cleared products – a consolidation of value towards the kit maker. The vacatur preserved the laboratories’ ability to build their own panels, which means the largest customers for syndromic testing are also potential competitors for it, and the price of a panel is capped by what a reference laboratory could reproduce internally.

That is the correct reading of the current position: the laboratory developed test framework is deflationary for kit pricing in the United States, which is good for testing volumes and difficult for kit margins. Any change to that framework changes the pricing power in this market more than any product launch would.

Europe: risk classification and notified body capacity

The European In Vitro Diagnostic Regulation replaced the earlier directive with a risk-based classification in which assays detecting transmissible agents, and assays used for blood and tissue compatibility, sit in the higher classes requiring notified body conformity assessment and substantially more analytical and clinical evidence. The transition has been staged rather than instantaneous, and the practical effects on this market are three.

Compliance cost per assay rises sharply, which favours participants with a broad menu that can absorb the cost across many products. Notified body capacity, rather than scientific capability, becomes the gate on how quickly a menu can be extended, which introduces a queue that is not responsive to commercial urgency. And the evidence burden falls hardest on exactly the decentralised, waived-style products where the growth is, because demonstrating lay-user performance is a different and more expensive exercise than demonstrating laboratory performance.

Prequalification and programme procurement

Outside the reimbursed markets, a large share of viral testing is purchased by ministries and donor-funded programmes, and access to those channels is governed by prequalification and registration rather than by a marketing authorisation alone. A product that is authorised in Europe but not prequalified cannot be sold into programme procurement; a product that is prequalified but not registered locally may still be blocked at the border.

This creates a regulatory barrier that operates independently of product quality and that favours incumbents with registration files in many jurisdictions. It also explains why the fastest-growing decentralised platforms are the ones that invested in registrations early: the barrier to entry in programme markets is administrative, and it is high.

What the regulatory position implies for the forecast

Three conclusions, and they bound the 8.76% path.

First, the durable revenue in this market is cleared or approved product sold into reimbursed or programme-funded channels. The volatile revenue is emergency-authorised product sold into declaration-driven demand. A market forecast has to distinguish them, and this one does: the forecast does not assume that emergency demand persists, and it does not assume that it disappears.

Second, the price ceiling in the United States is set by the laboratory developed test framework rather than by competition between kit makers alone. That is why the vacatur matters more than any individual clearance.

Third, the geography of growth is determined by registration and prequalification rather than by epidemiology. The markets where viral testing volumes will grow fastest are the ones where a kit maker has already spent the administrative cost of being allowed to sell.